Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06612970

A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants

The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

New Zealand Clinical Research

Christchurch, 8011, New Zealand

Location status: Recruiting

Location contact

Lucia Druzianic

CONTACT

[email protected]

+ 64 9 373 3474 ext. 7221

About this study

This is a single-dose escalation study of HB0056 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0056.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male or female subjects age ≥ 18 and ≤ 55 years.
  • Body Mass Index (BMI) ≥ 18 and ≤ 32 kg/m².
  • Normal ECG, blood pressure, respiratory rate, temperature, and heart rate, unless the investigator considers any abnormality to be not clinically significant.
  • Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation.

Exclusion criteria

  • History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease.
  • Current or history of malignancy. • Family history of premature Coronary Heart Disease (CHD)
  • History of clinically significant opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).
  • Pregnant or Breasting feeding subject. Women with a positive pregnancy test .
  • Further exclusions criteria applied.

Treatment and study plan

HB0056

Drug

HB0056 Injection

Other names: Targeting TSLP and IL-11 IgG1-type Bispecific Antibody

Placebo

Drug

Placebo

Other names: No other invention name

Primary outcomes

  1. Percentage of subjects with drug related adverse events (AEs)

    Time frame: Up to 2700 hours

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational drug

Secondary outcomes

  1. Cmax

    Time frame: Up to 2700 hours

    The maximum measured concentration of the analysis in plasma.

  2. AUC0-infinity

    Time frame: Up to 2700 hours

    The area under the concentration-time curve of the analysis in plasma over the time interval from 0 extrapolated to infinity

Study contacts

Contact information is provided by the study sponsor or research team.

Jingjing Wang

CONTACT

[email protected]

086 15002154126

Xiaoyan Liu

CONTACT

[email protected]

086 15002154126

Sponsors and collaborators

Lead sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0056 in Adult Healthy Subjects.

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 25, 2024
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.